Henry Schein Inc. has seen a series of ups and downs recently. Despite outperforming Q1 and Q2 earnings estimates, it experienced lowered sales views for 2024 and missed Q1 revenue. HSIC also appeared solid amidst market challenges but lowered FY2025 EPS estimates and faced a cyber attack in Q4 2023. Its Q1 earnings snapshot reflected these mixed results, with a certain boost from AI tools implemented in dental practices and the acquisition of Elite Computer Italia.
Many analysts rate HSIC as a 'Hold' with a target price around $81.09, yet HSIC stock traded 5.7% higher after strong earnings, and there were positive long-term outlooks. HSIC also strengthened its position with new acquisitions, consolidating a majority stake in Large Practice Sales and expanding into the orthopedic space with the purchase of TriMed. Facing macroeconomic challenges, Henry Schein enlisted a restructure plan and also bought a majority stake in Shield Healthcare.
Henry Schein HSIC News Analytics from Mon, 16 Oct 2023 07:00:00 GMT to Fri, 10 May 2024 12:11:54 GMT - Rating 1 - Innovation 2 - Information 7 - Rumor -4
